March 2026
1. ZHANG Z, Zhu D, Liu C, Gan L, et al
   Small Extracellular Vesicle External Surface Adiponectin-Mediated Adipocytes/Cardiomyocytes Communication in Diabetic Ischemic Heart Failure.
   Circulation. 2026 Mar 2. doi: 10.1161/CIRCULATIONAHA.125.076372.
   

   >> Share

   
   February 2026
2. XU Y, Huang T, Zhang Y, Ji D, et al
   Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation.
   Circulation. 2026 Feb 24. doi: 10.1161/CIRCULATIONAHA.125.075157.
   

   >> Share

   
   
3. HUNDERTMARK MJ, Birkhoelzer SM, Portwood C, Siu AG, et al
   IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.
   Circulation. 2026;153:550-563.
   

   >> Share

   
   January 2026
4. XU J, Wu Y, Song P, Zhang M, et al
   Retraction of: Proteasome-Dependent Degradation of Guanosine 5'-Triphosphate Cyclohydrolase I Causes Tetrahydrobiopterin Deficiency in Diabetes Mellitus.
   Circulation. 2026 Jan 30. doi: 10.1161/CIR.0000000000001420.
   

   >> Share

   
   
5. ZHAO YT
   Letter by Zhao Regarding Article, "Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial".
   Circulation. 2026;153:e8-e9.
   

   >> Share

   
   September 2025
6. SHI F, Zheng B, Liu Y
   Letter by Shi et al Regarding Article "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality".
   Circulation. 2025;152:e71-e72.
   

   >> Share

   
   
7. SILBERNAGEL G, Wen Y, Konrad RJ
   Response by Silbernagel et al to Letters Regarding Article, "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality".
   Circulation. 2025;152:e73-e74.
   

   >> Share

   
   
8. HUANG J
   Letter by Huang Regarding Article, "Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality".
   Circulation. 2025;152:e69-e70.
   

   >> Share

   
   August 2025
9. GAO P, Cao M, Wang X, Zhang H, et al
   G Protein-Coupled Receptor Kinase 3 Exacerbates Diabetic Heart Injuries Through Direct Phosphorylation of Cannabinoid Receptor 2 in Humans and Mice.
   Circulation. 2025 Aug 7. doi: 10.1161/CIRCULATIONAHA.125.073947.
   

   >> Share

   
   May 2025
10. WANG C, Shen S, Kang J, Sugai-Munson A, et al
    METTL3 Is Essential for Exercise Benefits in Diabetic Cardiomyopathy.
    Circulation. 2025 May 13. doi: 10.1161/CIRCULATIONAHA.124.070279.
    

    >> Share

    
    
11. SATTAR N, Weerakkody GJ, McGuire DK, Kosiborod MN, et al
    The Association Between Tirzepatide Versus Insulin Glargine and NT-proBNP Levels in People With Type 2 Diabetes With or at Elevated Risk for Cardiovascular Disease: Post hoc Analyses of SURPASS 4.
    Circulation. 2025;151:1430-1432.
    

    >> Share

    
    April 2025
12. DONG J, Yang X, Zhang W
    Letter by Dong et al Regarding Article, "Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation".
    Circulation. 2025;151:e962-e963.
    

    >> Share

    
    
13. BONNESEN K, Heide-Jorgensen U, Schmidt M
    Response by Bonnesen et al to Letter Regarding Article, "Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation".
    Circulation. 2025;151:e964.
    

    >> Share

    
    March 2025
14. MARX N, Deanfield JE, Mann JFE, Arechavaleta R, et al
    Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.
    Circulation. 2025 Mar 29. doi: 10.1161/CIRCULATIONAHA.125.074545.
    

    >> Share

    
    February 2025
15. YU AYX, Auger N, Fu L, Chu A, et al
    Population-Level Screening for Diabetes and Dyslipidemia After Pregnancies Complicated by Hypertension or Diabetes.
    Circulation. 2025;151:508-510.
    

    >> Share

    
    January 2025
16. 
    Correction to: Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.
    Circulation. 2025;151:e30.
    

    >> Share

    
    
17. MORDI IR, McCrimmon RJ, Lang CC
    SGLT Inhibitors in Persons With Heart Failure and Type 1 Diabetes: Filling the Therapeutic Gap.
    Circulation. 2025;151:199-201.
    

    >> Share

    
    December 2024
18. BIRKENFELD AL, Franks PW, Mohan V
    Precision Medicine in People at Risk for Diabetes and Atherosclerotic Cardiovascular Disease: A Fresh Perspective on Prevention.
    Circulation. 2024;150:1910-1912.
    

    >> Share

    
    October 2024
19. SILBERNAGEL G, Chen YQ, Li H, Lemen D, et al
    Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality.
    Circulation. 2024 Oct 11. doi: 10.1161/CIRCULATIONAHA.124.069272.
    

    >> Share

    
    August 2024
20. NEUEN BL, Fletcher RA, Heath L, Perkovic A, et al
    Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Circulation. 2024 Aug 30. doi: 10.1161/CIRCULATIONAHA.124.071689.
    

    >> Share

    
    
21. BONNESEN K, Heide-Jorgensen U, Christensen DH, Lash TL, et al
    Comparative Cardiovascular Effectiveness of Empagliflozin Versus Dapagliflozin in Adults With Treated Type 2 Diabetes: A Target Trial Emulation.
    Circulation. 2024 Aug 29. doi: 10.1161/CIRCULATIONAHA.124.068613.
    

    >> Share

    
    
22. GOPALASINGAM N, Berg-Hansen K, Christensen KH, Ladefoged BT, et al
    Randomized Crossover Trial of 2-Week Ketone Ester Treatment in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction.
    Circulation. 2024 Aug 20. doi: 10.1161/CIRCULATIONAHA.124.069732.
    

    >> Share

    
    
23. RAJAGOPALAN S, Dobre M, Dazard JE, Vergara-Martel A, et al
    Mineralocorticoid Receptor Antagonism Prevents Aortic Plaque Progression and Reduces Left Ventricular Mass and Fibrosis in Patients With Type 2 Diabetes and Chronic Kidney Disease: The MAGMA Trial.
    Circulation. 2024 Aug 12. doi: 10.1161/CIRCULATIONAHA.123.067620.
    

    >> Share

    
    July 2024
24. NEUEN BL, Claggett BL, Perkovic V, Jardine M, et al
    Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials.
    Circulation. 2024;150:343-345.
    

    >> Share

    
    June 2024
25. TANNU M, Kaltenbach L, Pagidipati NJ, McGuire DK, et al
    Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial.
    Circulation. 2024 Jun 27. doi: 10.1161/CIRCULATIONAHA.124.068962.
    

    >> Share

    
    April 2024
26. NEUEN BL, Tuttle KR, Vaduganathan M
    Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease.
    Circulation. 2024;149:1238-1240.
    

    >> Share

    
    
27. BLOOD AJ, Chang LS, Hassan S, Chasse J, et al
    Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069494.
    

    >> Share

    
    
28. PATEL SM, Kang YM, Im K, Neuen BL, et al
    Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
    Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069568.
    

    >> Share

    
    March 2024
29. BILLING AM, Kim YC, Gullaksen S, Schrage B, et al
    Metabolic Communication by SGLT2 Inhibition.
    Circulation. 2024;149:860-884.
    

    >> Share

    
    
30. GABA P, Sabik JF, Murphy SA, Bellavia A, et al
    Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials.
    Circulation. 2024 Mar 11. doi: 10.1161/CIRCULATIONAHA.123.065571.
    

    >> Share

    
    December 2023
31. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
    Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
    Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share